Ablacon

About Ablacon

Ablacon, Inc., founded in 2015 by Dr. Philip Haeusser, is a medical technology company that has developed an advanced, AI-powered system for the diagnosis and treatment of atrial fibrillation (AFib). The company's core product is the Ablamap® X, an investigational mapping system that uses artificial intelligence to analyze and visualize the flow of action potentials in the heart, what the company refers to as "Electrographic Flow." This technology aims to provide physicians with a real-time, high-precision tool to identify the specific areas of the heart that are driving AFib, enabling more targeted and effective ablation therapy.

The company's business model is centered on the development and sale of its proprietary medical devices and software to hospitals and electrophysiology labs. By providing a more precise and individualized approach to AFib treatment, Ablacon seeks to improve patient outcomes and reduce the high recurrence rates associated with traditional ablation procedures. The company serves the cardiology market, with a specific focus on electrophysiologists who perform cardiac ablation procedures.

Dr. Philip Haeusser, the founder and CTO of Ablacon, has a background in computer vision and deep learning, which he has leveraged to develop the company's innovative technology. His expertise in these fields has been instrumental in creating a system that can analyze complex cardiac signals and provide physicians with actionable insights.